ES3047718T3 - Cereblon binding compounds, compositions thereof, and methods of treatment therewith - Google Patents

Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Info

Publication number
ES3047718T3
ES3047718T3 ES21829558T ES21829558T ES3047718T3 ES 3047718 T3 ES3047718 T3 ES 3047718T3 ES 21829558 T ES21829558 T ES 21829558T ES 21829558 T ES21829558 T ES 21829558T ES 3047718 T3 ES3047718 T3 ES 3047718T3
Authority
ES
Spain
Prior art keywords
methyl
trans
dimethyl
oxo
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21829558T
Other languages
English (en)
Spanish (es)
Inventor
Matthew D Alexander
Matthew D Correa
Deepak Dalvie
Virginia Heather Sharron Grant
Joshua Hansen
Harris, Iii
Evan J Horn
Dehua Huang
Christopher Mayne
Stephen Norris
Veronique Plantevin-Krenitsky
John J Sapienza
Lida Tehrani
Brandon W Whitefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ES3047718T3 publication Critical patent/ES3047718T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES21829558T 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith Active ES3047718T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043650P 2020-06-24 2020-06-24
PCT/US2021/038629 WO2021262815A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
ES3047718T3 true ES3047718T3 (en) 2025-12-04

Family

ID=79167578

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21829558T Active ES3047718T3 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Country Status (9)

Country Link
US (1) US11560371B2 (https=)
EP (1) EP4171567B1 (https=)
JP (1) JP7781083B2 (https=)
KR (1) KR20230027214A (https=)
CN (1) CN115968293B (https=)
AR (1) AR122726A1 (https=)
ES (1) ES3047718T3 (https=)
TW (1) TW202216690A (https=)
WO (1) WO2021262815A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
CN110317192A (zh) 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Also Published As

Publication number Publication date
EP4171567B1 (en) 2025-09-03
CN115968293A (zh) 2023-04-14
JP2023531495A (ja) 2023-07-24
CN115968293B (zh) 2025-08-26
AR122726A1 (es) 2022-09-28
EP4171567A4 (en) 2024-07-24
JP7781083B2 (ja) 2025-12-05
US11560371B2 (en) 2023-01-24
EP4171567A1 (en) 2023-05-03
TW202216690A (zh) 2022-05-01
US20220002273A1 (en) 2022-01-06
KR20230027214A (ko) 2023-02-27
WO2021262815A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
ES3048462T3 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
ES3047718T3 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
JP7781792B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
BR112021012186A2 (pt) Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
KR20240026939A (ko) 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
KR20240025613A (ko) 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022272053A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
EA047871B1 (ru) Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith